{"id":"standard-chemotherapy-for-colorectal-cancer","safety":{"commonSideEffects":[{"rate":"20-50%","effect":"Nausea"},{"rate":"30-60%","effect":"Fatigue"},{"rate":"10-30%","effect":"Hair loss"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-15%","effect":"Vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This is achieved through the disruption of DNA replication and cell division, which are essential processes for cancer cell proliferation. The exact mechanism can vary depending on the specific chemotherapy agent used, but the overall goal is to slow or stop the growth of cancer cells.","oneSentence":"Standard chemotherapy for colorectal cancer works by interfering with the growth of cancer cells, ultimately leading to cell death.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:53:26.059Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic colorectal cancer"}]},"trialDetails":[{"nctId":"NCT05379595","phase":"PHASE1, PHASE2","title":"A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-07-29","conditions":"Advanced or Metastatic Colorectal Cancer","enrollment":225},{"nctId":"NCT07044362","phase":"NA","title":"Histotripsy Plus Chemotherapy vs Chemotherapy Alone for Advanced Colorectal Liver Metastasis","status":"RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2025-06-30","conditions":"Colorectal Cancer, Liver Metastases, Liver Cancer","enrollment":100},{"nctId":"NCT07472868","phase":"PHASE3","title":"Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"J. W. A. Burger","startDate":"2026-03-03","conditions":"Locally Advanced Rectal Carcinoma","enrollment":394},{"nctId":"NCT05845450","phase":"PHASE2","title":"Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)","status":"RECRUITING","sponsor":"Gruppo Oncologico del Nord-Ovest","startDate":"2023-05-11","conditions":"Colorectal Cancer, Resectable Colorectal Carcinoma","enrollment":197},{"nctId":"NCT06011772","phase":"EARLY_PHASE1","title":"EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2023-12-18","conditions":"Colo-rectal Cancer","enrollment":2},{"nctId":"NCT05239741","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-04-02","conditions":"Colorectal Neoplasms","enrollment":100},{"nctId":"NCT06279130","phase":"PHASE2, PHASE3","title":"Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2024-01-29","conditions":"Resectable MMR-deficient Solid Tumors, Resectable MMR-proficient Solid Tumors","enrollment":133},{"nctId":"NCT06071052","phase":"PHASE2","title":"TACE Plus HAIC Combined With Regorafenib for Liver Metastasis of Colorectal Cancer Refractory to Standard Treatment Regimens","status":"COMPLETED","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2023-12-01","conditions":"Liver Metastasis Colon Cancer","enrollment":21},{"nctId":"NCT04094688","phase":"PHASE3","title":"Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2019-10-29","conditions":"Colorectal Adenocarcinoma","enrollment":455},{"nctId":"NCT06047379","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","status":"RECRUITING","sponsor":"Neonc Technologies, Inc.","startDate":"2023-11-01","conditions":"Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult","enrollment":134},{"nctId":"NCT06546553","phase":"PHASE1","title":"A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.","status":"TERMINATED","sponsor":"Pfizer","startDate":"2024-09-06","conditions":"Neoplasms, Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck","enrollment":10},{"nctId":"NCT07413146","phase":"NA","title":"Neoadjuvant CAPEOX Versus Upfront Surgery for Locally Advanced Colon Cancer With Elevated CEA: A Single-Center, Open-Label, Randomized Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-02-24","conditions":"Minimal Residual Disease, Immunoscore, Neoadjuvant Chemotherapy","enrollment":100},{"nctId":"NCT07405476","phase":"PHASE2","title":"Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment","status":"NOT_YET_RECRUITING","sponsor":"Emory University","startDate":"2026-03-01","conditions":"Colon Carcinoma, Colorectal Carcinoma, Rectal Carcinoma","enrollment":38},{"nctId":"NCT06728072","phase":"PHASE2","title":"Addition of Antibiotics to Upfront Treatment Regimen for Colorectal Cancer","status":"RECRUITING","sponsor":"Virginia Commonwealth University","startDate":"2025-03-07","conditions":"Colorectal Cancer, CRC","enrollment":97},{"nctId":"NCT02956876","phase":"PHASE3","title":"Equivalence of Monitoring by a Nurse Practitioner for Patients With Digestive Cancer","status":"COMPLETED","sponsor":"University Hospital, Rouen","startDate":"2016-12-05","conditions":"ColoRectal Cancer","enrollment":207},{"nctId":"NCT05175092","phase":"NA","title":"Living Donor Liver Transplantation for CRC Liver Metastases","status":"WITHDRAWN","sponsor":"University of Wisconsin, Madison","startDate":"2023-11","conditions":"Liver Metastasis Colon Cancer","enrollment":""},{"nctId":"NCT07391618","phase":"PHASE2","title":"Clinical Study on the First-line Treatment of Advanced Colorectal Cancer With Simultaneous Infusion of Levozolinate for Injection and 5-FU","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2025-05-15","conditions":"Advanced Colorectal Cancer","enrollment":583},{"nctId":"NCT07389265","phase":"PHASE3","title":"Continuation of Cetuximab Beyond First-Line Progression in Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2025-10-01","conditions":"Metastatic Colorectal Cancer (mCRC)","enrollment":480},{"nctId":"NCT04587128","phase":"PHASE2","title":"Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2020-10-19","conditions":"Metastatic Colorectal Cancer","enrollment":34},{"nctId":"NCT07381764","phase":"PHASE2","title":"ROMANCE: \"Irinotecan Plus Cetuximab Rechallenge Versus Trifluridine/Tipiracil Plus Bevacizumab in Molecularly Selected Metastatic Colorectal Cancer\"","status":"NOT_YET_RECRUITING","sponsor":"Gruppo Oncologico Italia Meridionale","startDate":"2026-03-30","conditions":"Metastatic Colorectal Cancer (CRC)","enrollment":150},{"nctId":"NCT07381309","phase":"PHASE2","title":"Oncolytic Virus (H101) + SBRT + Chemotherapy + Targeted Therapy + Immunotherapy for Unresectable CRLM","status":"NOT_YET_RECRUITING","sponsor":"Jun Huang","startDate":"2026-02-01","conditions":"CRC, Liver Metastasis Colon Cancer","enrollment":114},{"nctId":"NCT06195514","phase":"","title":"Expanded Access to TAK-113 for Adults With Metastatic Colorectal Cancer (mCRC)","status":"NO_LONGER_AVAILABLE","sponsor":"Takeda","startDate":"","conditions":"Colorectal Cancer","enrollment":""},{"nctId":"NCT06199232","phase":"NA","title":"Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peking University","startDate":"2024-01-23","conditions":"Liver Metastasis Colon Cancer, ctDNA Genotype, MSS","enrollment":47},{"nctId":"NCT03697304","phase":"PHASE2","title":"Platform Trial Evaluating Safety and Efficacy of Ezabenlimab Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced/Metastatic Solid Tumours","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-03-19","conditions":"Neoplasm Metastasis, Advanced Tumors, Metastatic Solid Tumors","enrollment":211},{"nctId":"NCT07286695","phase":"PHASE2","title":"Fruquintinib Combined With Trifluridine/Tipiracil Versus Bevacizumab Combined With Trifluridine/Tipiracil for Advanced Metastatic Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-12-31","conditions":"Metastatic Colorectal Cancer (CRC), Colorectal Cancer","enrollment":292},{"nctId":"NCT06499129","phase":"NA","title":"LevineConservationModelandColorectalPatients","status":"COMPLETED","sponsor":"KTO Karatay University","startDate":"2025-06-25","conditions":"Fatigue, Peripheral Neuropathy, Anxiety","enrollment":68},{"nctId":"NCT07340567","phase":"PHASE3","title":"Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test","status":"NOT_YET_RECRUITING","sponsor":"UNICANCER","startDate":"2026-05-01","conditions":"Colorectal Cancer","enrollment":2450},{"nctId":"NCT04796818","phase":"NA","title":"An Investigational Scan (Intravoxel Incoherent Motion Diffusion Weighted Imaging) for the Evaluation of Colorectal Cancer Liver Metastases Treatment Response","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-08-12","conditions":"Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Resectable Colorectal Carcinoma","enrollment":70},{"nctId":"NCT07341217","phase":"NA","title":"Chemo Brain Prehab Project","status":"NOT_YET_RECRUITING","sponsor":"Dr. Chris Gaffney","startDate":"2026-01-30","conditions":"Colorectal Cancer, Older Adults (60 - 85 Years Old), Physically Inactive","enrollment":86},{"nctId":"NCT07333651","phase":"PHASE2","title":"125I Seed Implantation Plus Systemic Therapy for Oligoprogressive NSCLC or Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Li Min","startDate":"2026-01","conditions":"Oligometastatic Disease","enrollment":90},{"nctId":"NCT07334587","phase":"NA","title":"Comparison of Efficacy and Safety Between FOLFOX-6 and CAPOX in Metastatic Colorectal Carcinoma","status":"ENROLLING_BY_INVITATION","sponsor":"Allama Iqbal Medical College","startDate":"2025-09-01","conditions":"Metastatic Colorectal Carcinoma (mCRC)","enrollment":248},{"nctId":"NCT03599752","phase":"PHASE2","title":"Chemotherapy and/or Metastasectomy in Treating Patients With Metastatic Colorectal Adenocarcinoma With Lung Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-07-02","conditions":"Colorectal Adenocarcinoma, Colorectal Carcinoma Metastatic in the Lung, Stage IV Colorectal Cancer AJCC v8","enrollment":40},{"nctId":"NCT07328087","phase":"EARLY_PHASE1","title":"COLONYVAQ™, a Quantum-Classical Guided Personalized Neoantigen Vaccine for MSS Stage III Colorectal Cancer","status":"RECRUITING","sponsor":"Biogenea Pharmaceuticals Ltd.","startDate":"2026-02-02","conditions":"Colorectal Cancer Metastatic, Colorectal Cancer Stage III, Colorectal Cancer Stage IV","enrollment":12},{"nctId":"NCT06838338","phase":"PHASE1","title":"JAB-21822 Combined With Chemotherapy and Bevacizumab in Second-line KRAS G12C CRC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jian Li","startDate":"2025-03-20","conditions":"Colorectal Cancer","enrollment":30},{"nctId":"NCT07229846","phase":"PHASE2","title":"A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation","status":"NOT_YET_RECRUITING","sponsor":"Yanqiao Zhang","startDate":"2026-02","conditions":"Colorectal Cancer","enrollment":30},{"nctId":"NCT07321847","phase":"PHASE2, PHASE3","title":"Injection of IP-001 Into Thermally Ablated Hepatic Tumors in Patients With Colorectal Liver Metastases","status":"NOT_YET_RECRUITING","sponsor":"Immunophotonics, Inc.","startDate":"2026-05","conditions":"Colorectal Cancer (CRC), Colon Cancer Liver Metastases, Rectal Cancer","enrollment":717},{"nctId":"NCT05047536","phase":"PHASE1","title":"KZR-261 in Subjects With Advanced Solid Malignancies","status":"TERMINATED","sponsor":"Kezar Life Sciences, Inc.","startDate":"2021-09-30","conditions":"Advanced/Metastatic Solid Tumor","enrollment":61},{"nctId":"NCT06714357","phase":"PHASE2","title":"ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/Revert Resistance in Colorectal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute, Naples","startDate":"2025-03-12","conditions":"Colorectal Cancer Metastatic","enrollment":130},{"nctId":"NCT07283575","phase":"","title":"Using ctDNA Methylation to Monitor Metastatic Colorectal Cancer Treatment (PROMET)","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-10-10","conditions":"Metastatic Colorectal Cancer ctDNA Surveillance","enrollment":497},{"nctId":"NCT07198581","phase":"NA","title":"AI-Assisted Chemotherapy Side Effect Management","status":"RECRUITING","sponsor":"Incheon St.Mary's Hospital","startDate":"2025-11-12","conditions":"Breast Cancer, Colorectal Cancer","enrollment":174},{"nctId":"NCT04329494","phase":"PHASE1","title":"PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer","status":"RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2020-08-21","conditions":"Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8","enrollment":49},{"nctId":"NCT07271355","phase":"PHASE3","title":"Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colorectal Cancer With Peritoneal Metastases, The IMPACT Trial","status":"NOT_YET_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-07-01","conditions":"Metastatic Appendix Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Peritoneum","enrollment":129},{"nctId":"NCT07268677","phase":"PHASE2","title":"A Single-arm Clinical Study Evaluating Pirfenidone and Sintilimab in Combination With Standard Neoadjuvant Chemotherapy for Colorectal Cancer Patients With Peritoneal Metastasis.","status":"NOT_YET_RECRUITING","sponsor":"Guoxiang Cai","startDate":"2025-12-01","conditions":"Colorectal Cancer","enrollment":30},{"nctId":"NCT07260058","phase":"PHASE1, PHASE2","title":"Immune Cell Therapy for Advanced Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.","startDate":"2025-12-01","conditions":"Lung Cancer (Locally Advanced or Metastatic), Liver Cancer (Locally Advanced or Metastatic), Colorectal Cancer (Locally Advanced or Metastatic)","enrollment":48},{"nctId":"NCT06333314","phase":"PHASE2","title":"Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2024-07-23","conditions":"Pancreatic Adenocarcinoma, Ampulla of Vater Carcinoma, Adrenocortical Carcinoma","enrollment":120},{"nctId":"NCT06783491","phase":"PHASE3","title":"Efficacy of the Use of Neoadjuvant With/Without Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Locally Advanced Colon Cancer","status":"NOT_YET_RECRUITING","sponsor":"Maimónides Biomedical Research Institute of Córdoba","startDate":"2025-12-31","conditions":"Locally Advanced Colorectal Cancer","enrollment":1083},{"nctId":"NCT07234682","phase":"","title":"Impact of Anxiety-Sleep Symptom Cluster on Immune Function and Quality of Life in Colorectal Cancer","status":"COMPLETED","sponsor":"Hebei Provincial Hospital of Traditional Chinese Medicine","startDate":"2024-01-01","conditions":"Colorectal Cancer (MSI-H), Anxiety","enrollment":103},{"nctId":"NCT07158164","phase":"PHASE4","title":"DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment","status":"RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2025-08-27","conditions":"Colorectal Neoplasms, Breast Neoplasms, Head and Neck Neoplasms","enrollment":100},{"nctId":"NCT03594630","phase":"EARLY_PHASE1","title":"Active Surveillance and Chemotherapy Before Surgery in Treating Participants With Stage II-III Rectal Cancer","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-03-13","conditions":"Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8, Stage IIA Rectal Cancer AJCC v8","enrollment":120},{"nctId":"NCT07167446","phase":"EARLY_PHASE1","title":"Neuroprotective Potential of Cannabidiol (CBD) in Preventing Oxaliplatin (Ox)-Induced Neuropathy","status":"RECRUITING","sponsor":"Fox Chase Cancer Center","startDate":"2025-10-14","conditions":"Oxaliplatin Induced Peripheral Neuropathy in Cancer Patients, Metastatic Colorectal Cancer (CRC), Peripheral Neuropathy Due to Chemotherapy","enrollment":30},{"nctId":"NCT05510895","phase":"PHASE2","title":"Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients With BRAF V600E Mutated/pMMR Localized Colorectal Cancer","status":"COMPLETED","sponsor":"AIO-Studien-gGmbH","startDate":"2022-09-01","conditions":"Colorectal Cancer, Colon Cancer, BRAF V600E","enrollment":2},{"nctId":"NCT04607421","phase":"PHASE3","title":"A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2020-12-21","conditions":"Neoplasms","enrollment":831},{"nctId":"NCT04717375","phase":"PHASE1, PHASE2","title":"Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Sanofi","startDate":"2021-04-11","conditions":"Cancer, Neoplasm","enrollment":125},{"nctId":"NCT07025850","phase":"PHASE1, PHASE2","title":"Efficacy Study of Digoxin Combined With Serplulimab and Chemotherapy in First-Line Treatment of MSS Advanced Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2025-08-01","conditions":"Colorectal Carcinoma","enrollment":20},{"nctId":"NCT06839092","phase":"PHASE3","title":"Prophylactic PIPAC in Patients With High-risk Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Jeremy Meyer","startDate":"2026-01","conditions":"Colorectal Cancer Control and Prevention, Colorectal Cancer, Colorectal Cancer Stage II","enrollment":160},{"nctId":"NCT06279351","phase":"PHASE2","title":"Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer","status":"RECRUITING","sponsor":"Xinqiao Hospital of Chongqing","startDate":"2024-08-11","conditions":"Thalidomide Enhances Clinical Efficacy of Cetuximab Combined With Standard Chemotherapy for Left Colorectal Cancer","enrollment":96},{"nctId":"NCT06938971","phase":"NA","title":"Randomized Controlled Trial of the Effects of Combined Resistance and AerobiC Exercise on Health-related Quality of Life in Patients Undergoing First-line Chemotherapy for Metastatic Colorectal Cancer (REACH)","status":"RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2025-05-16","conditions":"Metastatic Colorectal Cancer (mCRC)","enrollment":150},{"nctId":"NCT06208371","phase":"PHASE3","title":"Localized Treatment Versus Palliative Chemotherapy in CRC Patients With 10 or More CRLM","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-01-15","conditions":"Colorectal Neoplasms Malignant","enrollment":117},{"nctId":"NCT06997458","phase":"","title":"Liquid BiOpsy, Lung and Colon Cancer in AndaluciA","status":"ENROLLING_BY_INVITATION","sponsor":"Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental","startDate":"2024-08-01","conditions":"Non Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)","enrollment":500},{"nctId":"NCT04813627","phase":"","title":"Epidemiological Study to Monitor Study Participants With Resected Stage II (High Risk) or Stage III Colorectal Cancer for Circulating Tumor DNA Before, During and After Their Treatment With Adjuvant Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"BioNTech SE","startDate":"2021-07-02","conditions":"Colorectal Cancer Stage II, Colorectal Cancer Stage III","enrollment":2200},{"nctId":"NCT03001362","phase":"NA","title":"Patients With Rectal Cancer: a \"Wait-and-see\" Approach","status":"RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2015-03","conditions":"Colorectal Carcinoma","enrollment":48},{"nctId":"NCT06946004","phase":"NA","title":"Normobaric Oxygen Therapy in Colorectal Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"4th Military Clinical Hospital with Polyclinic, Poland","startDate":"2025-11-01","conditions":"Colorectal Cancer (CRC)","enrollment":254},{"nctId":"NCT01792934","phase":"NA","title":"Chemotherapy and Maximal Tumor Debulking of Multi-organ Colorectal Cancer Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Radboud University Medical Center","startDate":"2013-05","conditions":"Multi-organ Metastatic Colorectal Cancer","enrollment":478},{"nctId":"NCT05710809","phase":"NA","title":"The SaVe Project-Sarcopenia and Vertigo in Aging Patients With Colorectal Cancer","status":"RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2023-02-20","conditions":"Colorectal Cancer, Oncologic Complications, Comprehensive Geriatric Assessment","enrollment":150},{"nctId":"NCT03597581","phase":"PHASE1","title":"A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer","status":"COMPLETED","sponsor":"Inspirna, Inc.","startDate":"2018-06-05","conditions":"Gastrointestinal Cancer, Gastrointestinal Neoplasms, Colorectal Cancer","enrollment":89},{"nctId":"NCT05646511","phase":"PHASE3","title":"TNT of SCRT+CAPOX vs SCRT+CAPOXIRI for Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"National Cancer Center Hospital East","startDate":"2022-11-21","conditions":"Locally Advanced Rectal Cancer","enrollment":608},{"nctId":"NCT05299840","phase":"NA","title":"Impact of Using the Oncogramme® Device to Select the First Line of Treatment for Patients With Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Oncomedics","startDate":"2023-06-07","conditions":"Metastatic Colorectal Cancer","enrollment":450},{"nctId":"NCT05576077","phase":"PHASE1","title":"A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Turnstone Biologics, Corp.","startDate":"2023-01-17","conditions":"Breast Cancer, Colorectal Cancer, Uveal Melanoma","enrollment":31},{"nctId":"NCT06855849","phase":"PHASE2","title":"An Open-label, Single-arm, Multicenter Phase II Study to Evaluate the Efficacy of Amivantamab in Combination With FOLFIRI as a Second-line Treatment in Patients With RAS/BRAF Wild-type Advanced Colorectal Cancer Progressing on Prior Anti-EGFR Based Treatment.","status":"NOT_YET_RECRUITING","sponsor":"Yonsei University","startDate":"2025-05","conditions":"RAS/BRAF Wild-type Advanced Colorectal Cancer Patients","enrollment":85},{"nctId":"NCT06857773","phase":"PHASE3","title":"Induction Treatment for Initially Unresectable Colorectal Liver Metastases: Combined Hepatic Arterial Infusion Pump Therapy With Systemic Therapy","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2024-11-21","conditions":"Colorectal Neoplasms, Floxuridine, Liver Metastases","enrollment":306},{"nctId":"NCT06849362","phase":"","title":"Multicenter Retrospective Study on Optimizing Combination Immunotherapy Strategies in MSS/MSI-L/pMMR Advanced Colorectal Cancer","status":"ENROLLING_BY_INVITATION","sponsor":"Yue Gou","startDate":"2019-12-01","conditions":"Metastatic Colorectal Cancer (CRC), MSS Metastatic Colorectal Cancer, Immunotherapy","enrollment":200},{"nctId":"NCT06843954","phase":"PHASE4","title":"Impact of Vascular Endothelial Growth Factor Gene Polymorphisms on Bevacizumab Efficacy in a Sample of Iraqi Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Mohammed Mahmood Mohammed","startDate":"2022-09-01","conditions":"Colo-rectal Cancer","enrollment":157},{"nctId":"NCT06841159","phase":"PHASE2","title":"Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy (PULSAR ) Combined With Anti-PD1，Chemotherapy and Target Therapy for Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-03-01","conditions":"Microsatellite Stable Metastatic Colorectal Cancer","enrollment":116},{"nctId":"NCT06456515","phase":"NA","title":"Regorafenib and Sintilimab in Combination with Electroacupuncture in MSS CRC","status":"RECRUITING","sponsor":"The First People's Hospital of Changzhou","startDate":"2024-05-01","conditions":"Colorectal Cancer Metastatic","enrollment":30},{"nctId":"NCT06830018","phase":"NA","title":"Nanocrystalline Megestrol for First-line Treatment of Advanced Gastric or Colorectal Cancer With Cancer-related Fatigue","status":"RECRUITING","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2025-01-23","conditions":"Cancer-related Fatigue， Gastric Cancer，Colorectal Cancer，Nano-crystalline Megestrol Acetate，Megestrol Acetate，First-line Treatment","enrollment":76},{"nctId":"NCT06794931","phase":"NA","title":"Study on the Impact of a Modified Mediterranean Diet, in Patients With Colorectal Cancer Undergoing Active Medical Oncology Treatment","status":"RECRUITING","sponsor":"Azienda Socio Sanitaria della Brianza","startDate":"2024-07-24","conditions":"Undefined","enrollment":40},{"nctId":"NCT06475352","phase":"PHASE2","title":"Dose Individualization of Chemotherapy in Patients With Gastrointestinal Cancers Lacking a Specific Liver Enzyme","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2025-01-20","conditions":"Digestive Cancer, Colorectal Cancer","enrollment":400},{"nctId":"NCT06425133","phase":"PHASE2","title":"Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2024-07-19","conditions":"Metastatic Colorectal Cancer","enrollment":174},{"nctId":"NCT05462613","phase":"PHASE2, PHASE3","title":"Regorafenib With Low-dose Chemotherapies and Aspirin Followed by Standard Chemotherapies in Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2023-05-09","conditions":"Metastatic Colorectal Cancer","enrollment":446},{"nctId":"NCT03009058","phase":"PHASE1, PHASE2","title":"Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer","status":"TERMINATED","sponsor":"Immodulon Therapeutics Ltd","startDate":"2017-05-31","conditions":"Metastatic Cancer","enrollment":2},{"nctId":"NCT04701476","phase":"PHASE2","title":"TATE and Pembrolizumab (MK3475) in mCRC and NSCLC","status":"RECRUITING","sponsor":"Teclison Ltd.","startDate":"2021-05-20","conditions":"Colorectal Cancer; Lung Cancer","enrollment":110},{"nctId":"NCT03374254","phase":"PHASE1","title":"Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651/KEYNOTE-651)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-02-16","conditions":"Metastatic Colorectal Cancer","enrollment":116},{"nctId":"NCT04840186","phase":"PHASE2","title":"EXtended CriteriA Treatment for LIver Metastases and Heavy Tumour BURden","status":"SUSPENDED","sponsor":"Oslo University Hospital","startDate":"2021-03-23","conditions":"Liver Metastases, Colorectal Cancer","enrollment":62},{"nctId":"NCT06411600","phase":"PHASE2","title":"Combination Therapy for BRAF-V600E Metastatic CRCm","status":"RECRUITING","sponsor":"Vall d'Hebron Institute of Oncology","startDate":"2024-05-17","conditions":"Metastatic Colorectal Cancer","enrollment":94},{"nctId":"NCT06520683","phase":"PHASE3","title":"Adjuvant PD-1 Blockade for High-risk Stage-II DMMR/MSI-H Colorectal Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-11-01","conditions":"Colorectal Cancer, Microsatellite Instability High","enrollment":180},{"nctId":"NCT04898504","phase":"PHASE2","title":"HAI-Floxuridine, or Liver-Tx, Combined With 2nd Line Chemotherapy Versus 2nd Line Chemotherapy Alone for Patients With Colorectal Liver Metastases and Heavy Tumour Burden.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Oslo University Hospital","startDate":"2021-08-23","conditions":"Colorectal Cancer, Liver Metastases, Chemotherapy Effect","enrollment":45},{"nctId":"NCT02704520","phase":"NA","title":"Magnetic Resonance Tumour Regression Grade (mrTRG) as a Novel Biomarker - Phase III Non CTIMP Trial","status":"RECRUITING","sponsor":"Imperial College London","startDate":"2016-03","conditions":"Rectal Cancer","enrollment":441},{"nctId":"NCT06275958","phase":"PHASE3","title":"DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2024-07-01","conditions":"Older Patients, Colorectal Cancer, Metastatic Cancer","enrollment":587},{"nctId":"NCT04021277","phase":"PHASE1","title":"PS101-mediated ACT With Chemotherapy in Liver Metastases From Cancer of Gastrointestinal Origin","status":"TERMINATED","sponsor":"EXACT Therapeutics AS","startDate":"2019-09-17","conditions":"Solid Tumor, Colorectal Cancer","enrollment":11},{"nctId":"NCT02175095","phase":"NA","title":"[18F]FLT-PET as a Predictive Imaging Biomaker of Treatment Responses to Regorafenib","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2014-07-18","conditions":"Colorectal Cancer","enrollment":68},{"nctId":"NCT02563002","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-11-30","conditions":"Colorectal Carcinoma","enrollment":307},{"nctId":"NCT02286492","phase":"","title":"Expanded Access Study of TAS-102 in Patients With Metastatic Colorectal Cancer","status":"APPROVED_FOR_MARKETING","sponsor":"Taiho Oncology, Inc.","startDate":"","conditions":"Colorectal Cancer Metastatic","enrollment":""},{"nctId":"NCT04680260","phase":"PHASE2","title":"OPTIMIzation of Treatment SElection and Follow up in Oligometastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Karen-Lise Garm Spindler","startDate":"2021-10-25","conditions":"Colorectal Cancer, Metastatic Cancer","enrollment":350},{"nctId":"NCT06525428","phase":"PHASE2","title":"Standard Systemic Therapy Combined With High/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Fudan University","startDate":"2024-04-01","conditions":"Microsatellite Stable Metastatic Colorectal Cancer","enrollment":96},{"nctId":"NCT03274882","phase":"PHASE2","title":"Study of Efficacy and Safety of S 95005 (TAS-102) in Patients With Metastatic Colorectal Cancer Who Failed Standard Chemotherapies","status":"COMPLETED","sponsor":"Institut de Recherches Internationales Servier","startDate":"2017-03-03","conditions":"Metastatic Colorectal Cancer","enrollment":26},{"nctId":"NCT05039944","phase":"PHASE2","title":"SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System Malignancies","status":"TERMINATED","sponsor":"Sichuan Baili Pharmaceutical Co., Ltd.","startDate":"2021-11-30","conditions":"Colorectal Cancer","enrollment":7},{"nctId":"NCT02842580","phase":"PHASE2","title":"De-escalation Chemotherapies Versus Escalation in Non Pre-treated Unresectable Patients With Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2016-09","conditions":"Colorectal Neoplasms","enrollment":21},{"nctId":"NCT05240625","phase":"NA","title":"Clinical Efficacy Evaluation of a Computer-aided Colonoscopy as Compared With the Standard Colonoscopy.","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2022-03-01","conditions":"Colon Adenoma, Colorectal Cancer","enrollment":1500},{"nctId":"NCT06421610","phase":"PHASE1","title":"OPC5: Pressurized IntraThoracic Aerosol Chemotherapy (PITAC) in Patients With Malignant Pleural Effusion.","status":"RECRUITING","sponsor":"Odense University Hospital","startDate":"2023-09-15","conditions":"Malignant Pleural Effusion, Pleural Neoplasms, Quality of Life","enrollment":20},{"nctId":"NCT06167967","phase":"NA","title":"Circulating Tumor DNA Methylation Guiding Postoperative Adjuvant Chemotherapy in Stage III Colorectal Cancer","status":"RECRUITING","sponsor":"Sir Run Run Shaw Hospital","startDate":"2024-04-08","conditions":"Colorectal Cancer","enrollment":990}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"standard chemotherapy for colorectal cancer","genericName":"standard chemotherapy for colorectal cancer","companyName":"University Hospital, Rouen","companyId":"university-hospital-rouen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Standard chemotherapy for colorectal cancer works by interfering with the growth of cancer cells, ultimately leading to cell death. Used for Metastatic colorectal cancer.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}